ly-3039478
Small moleculeexperimental
Clinical trial activity
8 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2012 (NCT01695005)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Breast Neoplasms · Phase 1
- Cholangiocarcinoma · Phase 1
- Colonic Neoplasms · Phase 1
- Healthy Volunteers · Phase 1
- Lymphoma · Phase 1
- Lymphoma, T-Cell · Phase 1/Phase 2
- Multiple Myeloma · Phase 1
- Neoplasm Metastasis · Phase 1
- Neoplasms · Phase 1
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma · Phase 1/Phase 2
- Sarcoma · Phase 1
Mechanism of action
NOTCH2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ly3039478
- ly3039478
- ly-3039478
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03502577 | Phase 1 | Sep 30, 2018 | Juno Therapeutics, Inc., The Leukemia and Lymphoma Society, University of Washington |
| NCT02784795 | Phase 1 | Nov 1, 2016 | Eli Lilly |
| NCT02906618 | Phase 1 | Oct 4, 2016 | Eli Lilly |
| NCT02836600 | Phase 1 | Sep 1, 2016 | Eli Lilly |
| NCT02917733 | Phase 1 | Sep 1, 2016 | Eli Lilly |
| NCT02659865 | Phase 1 | Jan 1, 2016 | Eli Lilly |
| NCT02518113 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2015 | Eli Lilly |
| NCT01695005 | Phase 1 | Oct 1, 2012 | Eli Lilly |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 7 | 7 | 2 | 2012 |
| Juno Therapeutics, Inc. | For profit | 1 | 0 | 1 | 2018 |
| The Leukemia and Lymphoma Society | Academic/Hospital | 1 | 0 | 1 | 2018 |
| University of Washington | Academic/Hospital | 1 | 1 | 1 | 2018 |
4 organizations
Page 1 / 1